Breast Disease Department, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, PR China.
Thyroid & Mammary Gland Surgery Department, Nanjing Jiangbei People's Hospital, Nanjing 210000, PR China.
Nanomedicine (Lond). 2019 Jun;14(12):1595-1603. doi: 10.2217/nnm-2018-0485. Epub 2019 Apr 12.
Compare the two-weekly regimens of nanoparticle albumin-bound paclitaxel (nab-P) with solvent-based paclitaxel (sb-P) as neoadjuvant chemotherapy for breast cancer. Patients (n = 162) with operable early breast cancer received four cycles of dose-dense epirubicin and cyclophosphamide followed by four two-weekly cycles of nab-P (n = 83) or sb-P (n = 79), with trastuzumab when needed. Across all the patients, the ypT0 ypN0 and ypT0/is ypN0 pathological complete response rates in the nab-P group were not superior to those in the sb-P group. However, pathological complete response rates for triple-negative breast cancer were significantly better with nab-P than with sb-P. Meanwhile, nab-P also induced more peripheral sensory neuropathy. The two-weekly nab-P regimen is a good neoadjuvant chemotherapy choice for triple-negative breast cancer.
将纳米白蛋白结合紫杉醇（nab-P）的两周方案与溶剂型紫杉醇（sb-P）作为乳腺癌的新辅助化疗进行比较。接受过密集型表柔比星和环磷酰胺治疗的 162 例可手术早期乳腺癌患者随后接受nab-P（n=83）或 sb-P（n=79）的四个两周周期治疗，有需要时还可使用曲妥珠单抗。在所有患者中，nab-P 组的 ypT0ypN0 和 ypT0/isypN0 病理完全缓解率并不优于 sb-P 组。然而，nab-P 治疗三阴性乳腺癌的病理完全缓解率明显优于 sb-P。同时，nab-P 还引起了更多的周围感觉神经病变。两周一次的 nab-P 方案是三阴性乳腺癌的一种较好的新辅助化疗选择。
